Ian Mortimer, chief executive officer of Xenon Pharmaceuticals Inc. ($XENE), bought 30,000 shares on September 30, 2026. The open-market purchase was executed at $37.38 per share, totaling $1,121,400. Mortimer filed the Form 4 with the SEC on October 1, 2026, one day after the transaction. He held 49,923 shares after the purchase.
Kelly Thomas Patrick, Xenon's chief financial officer, bought 15,000 shares the same day. His purchase price was $37.316 per share, for a total of $559,740. Patrick's Form 4 was also filed on October 1, 2026, and he held 15,000 shares afterward. Combined, the two September 30 open-market purchases totaled $1,681,140. Both transactions were reported the day after they were executed.
Daily price data for $XENE shows the stock closed at $37.19 on September 30, 2026, the day of the purchases. It closed at $37.25 on September 29, $36.72 on September 28, and $36.94 on September 25. The trade date opened at $37.38, matching Mortimer's per-share purchase price.
Mortimer's earlier $XENE filings show a series of sales during the first quarter of 2026. On March 13, 2026, he sold 7,308 shares at $55.225 per share, for a total of $403,584, and held 19,923 shares afterward. On March 10, 2026, he sold 11,269 shares at $60.108 per share, for $677,357, and held 14,731 shares afterward. On March 9, 2026, he filed multiple sales at prices between $58.81 and $62.06 per share, with reported totals ranging from $150,026 to $4,033,900. He also sold shares on January 2, 2026, at $44.40 and $44.93 per share, and on December 8, 2025, at $45.59 per share.
Other Xenon executives reported sales around the same period. Chief legal officer Andrea DiFabio sold 2,607 shares on March 10, 2026, at $60.108 per share, and 1,342 shares on March 13, 2026, at $55.225 per share. Her reported holdings after those sales were 4,893 and 7,301 shares, respectively. Chief medical officer Christopher John Kenney sold 2,771 shares on March 10, 2026, at $60.108 per share, and 1,410 shares on March 13, 2026, at $55.225 per share. His reported holdings after those sales were 4,729 and 7,069 shares, respectively.
The September 30 purchases were the only open-market purchases among the 20 most recent $XENE insider trades in the database. Xenon Pharmaceuticals is a biotechnology company with a market capitalization of about $6.2 billion. No congressional STOCK Act disclosures for $XENE were found in the database.